+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Schizophrenia - Pipeline Review, H1 2020

  • ID: 5117059
  • Drug Pipelines
  • May 2020
  • Region: Global
  • 383 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Biogen Inc
  • Daya Drug Discoveries Inc
  • GW Pharmaceuticals Plc
  • Luye Pharma Group Ltd
  • Otsuka Holdings Co Ltd
  • MORE
Schizophrenia - Pipeline Review, H1 2020

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Schizophrenia – Pipeline Review, H1 2020, provides an overview of the Schizophrenia (Central Nervous System) pipeline landscape.

Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior. Risk factors include family history, age, drugs (psychoactive) and weakened immune system. Treatment includes antipsychotic medications.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Schizophrenia – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Schizophrenia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Schizophrenia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 6, 1, 13, 15, 24, 3, 56 and 11 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 7 and 1 molecules, respectively.

Schizophrenia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Schizophrenia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Schizophrenia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Schizophrenia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Schizophrenia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Schizophrenia (Central Nervous System)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Schizophrenia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Schizophrenia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Biogen Inc
  • Daya Drug Discoveries Inc
  • GW Pharmaceuticals Plc
  • Luye Pharma Group Ltd
  • Otsuka Holdings Co Ltd
  • MORE
  • Introduction
  • Schizophrenia - Overview
  • Schizophrenia - Therapeutics Development
  • Schizophrenia - Therapeutics Assessment
  • Schizophrenia - Companies Involved in Therapeutics Development
  • Schizophrenia - Drug Profiles
  • Schizophrenia - Dormant Projects
  • Schizophrenia - Discontinued Products
  • Schizophrenia - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Schizophrenia, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Schizophrenia - Pipeline by AbbVie Inc, H1 2020
  • Schizophrenia - Pipeline by Acadia Pharmaceuticals Inc, H1 2020
  • Schizophrenia - Pipeline by Adamed Sp zoo, H1 2020
  • Schizophrenia - Pipeline by Adare Pharmaceuticals Inc, H1 2020
  • Schizophrenia - Pipeline by Adeptio Pharmaceuticals Ltd, H1 2020
  • Schizophrenia - Pipeline by Aequus Pharmaceuticals Inc, H1 2020
  • Schizophrenia - Pipeline by AgeneBio Inc, H1 2020
  • Schizophrenia - Pipeline by AgoneX Biopharmaceuticals Inc, H1 2020
  • Schizophrenia - Pipeline by Alkermes Plc, H1 2020
  • Schizophrenia - Pipeline by Athersys Inc, H1 2020
  • Schizophrenia - Pipeline by Autifony Therapeutics Ltd, H1 2020
  • Schizophrenia - Pipeline by Avanir Pharmaceuticals Inc, H1 2020
  • Schizophrenia - Pipeline by Avicanna Inc, H1 2020
  • Schizophrenia - Pipeline by AviMed Pharmaceuticals LLC, H1 2020
  • Schizophrenia - Pipeline by Avineuro Pharmaceuticals Inc, H1 2020
  • Schizophrenia - Pipeline by BCWorld Pharm Co Ltd, H1 2020
  • Schizophrenia - Dormant Projects, H1 2020
  • Schizophrenia - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Schizophrenia, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3
  • AbbVie Inc
  • Acadia Pharmaceuticals Inc
  • Adamed Sp zoo
  • Adare Pharmaceuticals Inc
  • Adeptio Pharmaceuticals Ltd
  • Aequus Pharmaceuticals Inc
  • AgeneBio Inc
  • AgoneX Biopharmaceuticals Inc
  • Alkermes Plc
  • Athersys Inc
  • Autifony Therapeutics Ltd
  • Avanir Pharmaceuticals Inc
  • Avicanna Inc
  • AviMed Pharmaceuticals LLC
  • Avineuro Pharmaceuticals Inc
  • BCWorld Pharm Co Ltd
  • Beloteca Inc
  • Biogen Inc
  • BioStem Technologies Inc
  • BioStratum Inc
  • BioXcel Therapeutics Inc
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co
  • Cadent Therapeutics Inc
  • Cerevance Inc
  • Cerevel Therapeutics LLC
  • Concert Pharmaceuticals Inc
  • Curemark LLC
  • CuroNZ Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Daya Drug Discoveries Inc
  • Delpor Inc
  • Denovo Biopharma LLC
  • Echo Pharmaceuticals BV
  • Enterin Inc
  • F. Hoffmann-La Roche Ltd
  • Fabre-Kramer Pharmaceuticals Inc
  • Gabather AB
  • Genentech Inc
  • GlaxoSmithKline Plc
  • GP Pharm SA
  • GW Pharmaceuticals Plc
  • H. Lundbeck AS
  • Impel NeuroPharma Inc
  • Indivior Plc
  • IntelGenx Corp
  • Intra-Cellular Therapies Inc
  • INVENT Pharmaceuticals Inc
  • IRLAB Therapeutics AB
  • Jiangsu Nhwa Pharmaceutical Co Ltd
  • Johnson & Johnson
  • Karuna Therapeutics Inc
  • Laboratorios Farmaceuticos Rovi SA
  • Lb Pharmaceuticals Inc
  • Lead Discovery Center GmbH
  • Lohocla Research Corp
  • Luye Pharma Group Ltd
  • Lyndra Inc
  • Mapi Pharma Ltd
  • MedinCell SA
  • Mental-Heal Ltd
  • Merck & Co Inc
  • Mitsubishi Tanabe Pharma Corp
  • Neurocea Pharmaceuticals
  • Neurocrine Biosciences Inc
  • NeurOp Inc
  • NeuroSolis Inc
  • Newron Pharmaceuticals SpA
  • Omeros Corp
  • Otsuka Holdings Co Ltd
  • Otsuka Pharmaceutical Co Ltd
  • OWP Pharmaceuticals Inc
  • Pfizer Inc
  • Ra Pharmaceuticals Inc
  • Reviva Pharmaceuticals Inc
  • Richter Gedeon Nyrt
  • Schrodinger LLC
  • Sichuan Kelun Pharmaceutical Co Ltd
  • Siragen Pharmaceuticals Inc
  • SkySea Pharmaceutical Inc
  • Sosei Heptares
  • Sumitomo Dainippon Pharma Co Ltd
  • Sunovion Pharmaceuticals Inc
  • SyneuRx International Corp
  • Taho Pharmaceuticals Ltd
  • Taisho Pharmaceutical Holdings Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Terran Biosciences Inc
  • Teva Pharmaceutical Industries Ltd
  • Vanda Pharmaceuticals Inc
  • Vitality Biopharma Inc
  • Zysis Ltd
Note: Product cover images may vary from those shown
Adroll
adroll